Enveric Biosciences Receives Notice of Allowance for EVM301 Series of Drug Candidates
Rhea-AI Impact
(High)
Rhea-AI Sentiment
(Positive)
Tags
Key Terms
notice of allowanceregulatory
A notice of allowance is an official confirmation from a patent office that a patent application has met all necessary requirements and is approved for granting. It signals that the invention is likely to receive legal protection soon, which can be important for investors considering the value and exclusivity of a new product or technology. Think of it as a green light indicating that the invention is on track to become legally protected.
usptoregulatory
United States Patent and Trademark Office (USPTO) is the federal agency that reviews and issues patents for inventions and registers trademarks for brand names and logos. For investors, USPTO decisions act like a gatekeeper for a company’s legal right to exclude competitors — similar to a property deed for ideas and brands — which can protect revenue, support pricing power, and affect a company’s long‑term value and risk profile.
n-heterocyclemedical
A N-heterocycle is an organic molecule whose ring structure includes at least one nitrogen atom instead of only carbon atoms. Because swapping a single atom in a ring can change how a molecule behaves—like replacing a brick in a wall to alter stability or function—nitrogen-containing rings are common in medicines, agrochemicals and materials; their presence often affects a drug’s potency, safety profile, patentability and manufacturing complexity, all important to investors.
tryptaminemedical
A tryptamine is a small organic molecule that serves as the basic chemical “building block” for a range of naturally occurring and synthetic compounds, including some neurotransmitters and psychedelic drugs. Investors should care because drugs and products built from this scaffold can drive new therapies or consumer offerings but also attract strict safety testing, regulatory control, and patent or market risk — much like a versatile Lego piece that can create either valuable or tightly regulated outcomes.
neuroplastogenicmedical
Neuroplastogenic describes a drug, molecule or treatment that actively promotes neuroplasticity — the brain’s ability to rewire itself by creating or strengthening connections between nerve cells. Think of it as encouraging a tangled garden path to be replanted and smoothed so signals travel more easily; for investors, neuroplastogenic activity can signal potential for lasting benefit in neurological or psychiatric disorders, larger market opportunity, and distinct regulatory and development risks.
5-ht₁bmedical
5‑HT1B is a specific type of serotonin receptor — a protein on nerve and blood vessel cells that responds when the brain’s chemical messenger serotonin binds to it. Think of it as a dimmer switch or lock that helps control mood, blood vessel tone and release of other brain signals; drugs that act on this receptor can change symptoms of conditions like migraine or depression. Investors watch it because it is a common drug target whose success or failure in clinical trials and regulatory review can strongly affect a therapy’s market potential.
anxiolyticmedical
An anxiolytic is a medication designed to reduce feelings of anxiety or panic, acting like a dimmer switch that tones down intense emotional responses without treating the underlying cause. Investors care because development, approval, patent protection, and patient uptake determine sales and profit potential; successful drugs can create steady revenue streams, while trial failures, safety warnings or generic competition can sharply reduce a product’s market value.
Once issued, this new U.S. Patent will expand the scope of Enveric’s EVM301 patent portfolio of potential neuroplastogenic molecules for treatment of neuropsychiatric conditions.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (“USPTO”) for a patent application pertaining to its EVM301 Series of molecules being developed as potential treatments for mental health disorders.
The USPTO issues a Notice of Allowance after making the determination that a patent should be granted from an application.
Entitled, “N-heterocycle substituted tryptamine derivatives and methods of using,” the application will add to the portfolio of patents issued for Enveric’s EVM301 Series of molecules. The compositions claims and methods of use claims covered by this patent will further broaden Enveric’s pipeline by covering additional potential neuroplastogenic non-hallucinogenic molecules and strengthening its potential to target neuropsychiatric and addiction disorders for patients with few other options.
“We continue to work diligently to reinforce our patent estate around our lead asset, EB-003 and the EVM301 Series of compounds, which we see as vital in order to generate value for Enveric shareholders,” said Joseph Tucker, Ph.D., Director and CEO of Enveric. “We believe EB-003 holds great potential as the first known compound designed to selectively engage both 5-HT₂A and 5-HT₁B receptors to deliver fast-acting, durable antidepressant and anxiolytic effects, while being specifically designed to promote neuroplasticity and minimize hallucinogenic effects, allowing administration in outpatient setting."
About Enveric Biosciences
Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company focused on developing next-generation, small-molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders. By leveraging a differentiated drug discovery platform and a growing library of protected chemical structures, Enveric is advancing a pipeline of novel compounds designed to promote neuroplasticity without hallucinogenic effects. Enveric’s lead candidate, EB-003, is the first known compound designed to selectively engage both 5-HT₂A and 5-HT₁B receptors to deliver fast-acting, durable antidepressant and anxiolytic effects with outpatient convenience.
This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as "plans," "expects" or "does not expect," "proposes," "budgets," "explores," "schedules," "seeks," “sees,” "estimates," "forecasts," "intends," "anticipates" or "does not anticipate," or "believes," or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, should, would, or might occur or be achieved. Forward-looking statements may include statements regarding beliefs, plans, expectations, or intentions regarding the future and are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the ability of Enveric to: finalize and submit its IND filing to the U.S. Food and Drug Administration; carry out successful clinical programs; achieve the value creation contemplated by technical developments; avoid delays in planned clinical trials; establish that potential products are efficacious or safe in preclinical or clinical trials; establish or maintain collaborations for the development of therapeutic candidates; obtain appropriate or necessary governmental approvals to market potential products; obtain future funding for product development and working capital on commercially reasonable terms; scale-up manufacture of product candidates; respond to changes in the size and nature of competitors; hire and retain key executives and scientists; secure and enforce legal rights related to Enveric’s products, including patent protection; identify and pursue alternative routes to capture value from its research and development pipeline assets; continue as a going concern; and manage its future growth effectively.
A discussion of these and other factors, including risks and uncertainties with respect to Enveric, is set forth in Enveric’s filings with the Securities and Exchange Commission, including Enveric’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Enveric disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
